JP4326022B2 - ＴＮＦ−α転換酵素 - Google Patents

ＴＮＦ−α転換酵素 Download PDF

Info

Publication number
JP4326022B2
JP4326022B2 JP50310797A JP50310797A JP4326022B2 JP 4326022 B2 JP4326022 B2 JP 4326022B2 JP 50310797 A JP50310797 A JP 50310797A JP 50310797 A JP50310797 A JP 50310797A JP 4326022 B2 JP4326022 B2 JP 4326022B2
Authority
JP
Japan
Prior art keywords
tace
polypeptide
tnf
isolated
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50310797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002515020A (ja
JP2002515020A5 (fr
Inventor
ブラック，ロイ・エイ
ローチ，チャールズ
マーチ，カール・ジェイ
セレッティ，ダグラス・ピー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,345 external-priority patent/US5830742A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of JP2002515020A publication Critical patent/JP2002515020A/ja
Publication of JP2002515020A5 publication Critical patent/JP2002515020A5/ja
Application granted granted Critical
Publication of JP4326022B2 publication Critical patent/JP4326022B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
JP50310797A 1995-06-08 1996-06-03 ＴＮＦ−α転換酵素 Expired - Fee Related JP4326022B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US48245895A 1995-06-08 1995-06-08
US08/428,458 1995-06-08
US50461495A 1995-07-20 1995-07-20
US08/504,614 1995-07-20
US08/655,345 US5830742A (en) 1995-06-08 1996-05-23 TNF-α converting enzyme
US08/655,345 1996-05-23
PCT/US1996/008407 WO1996041624A1 (fr) 1995-06-08 1996-06-03 Enzyme de conversion du facteur de necrose tumorale alpha

Publications (3)

Publication Number Publication Date
JP2002515020A JP2002515020A (ja) 2002-05-21
JP2002515020A5 JP2002515020A5 (fr) 2004-07-29
JP4326022B2 true JP4326022B2 (ja) 2009-09-02

Family

ID=27413615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50310797A Expired - Fee Related JP4326022B2 (ja) 1995-06-08 1996-06-03 ＴＮＦ−α転換酵素

Country Status (13)

Country Link
EP (1) EP0830130B9 (fr)
JP (1) JP4326022B2 (fr)
AT (1) ATE274346T1 (fr)
AU (1) AU712759C (fr)
CA (1) CA2222650C (fr)
DE (1) DE69633231T2 (fr)
DK (1) DK0830130T3 (fr)
ES (1) ES2227598T3 (fr)
IL (1) IL122305A0 (fr)
NO (1) NO323623B1 (fr)
NZ (2) NZ510390A (fr)
PT (1) PT830130E (fr)
WO (1) WO1996041624A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US6255064B1 (en) 1996-03-01 2001-07-03 The Procter & Gamble Company Disintegrin metalloprotease and its use
JP2000507943A (ja) * 1996-03-26 2000-06-27 グラクソ、グループ、リミテッド 腫瘍壊死因子αコンバーターゼ
EP0912746A2 (fr) * 1996-07-12 1999-05-06 Schering Corporation Fnt-alpha convertase mammalienne
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6046031A (en) * 1997-01-21 2000-04-04 Human Genome Sciences, Inc. Metalloproteinases
HUP0100780A2 (hu) * 1997-02-25 2001-06-28 Case Western Reserve University Új dezintegrin metalloproteáz, mutánsai, fragmentumai és hasonlók alkalmazása
US6551857B2 (en) 1997-04-04 2003-04-22 Elm Technology Corporation Three dimensional structure integrated circuits
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
EP1053304B1 (fr) * 1998-02-04 2007-07-04 Immunex Corporation Enzyme de conversion cristalline du facteur tnf alpha et ses utilisations
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
EP1449538A1 (fr) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de TACE ou amphirégulin pour moduler la transactivation de signaux récepteur EGF
WO2005030798A2 (fr) * 2003-09-24 2005-04-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Agents inhibiteurs et agents stimulateurs de l'enzyme de conversion du tnf-$g(a)
DK2061803T4 (da) 2006-08-28 2022-12-05 Ares Trading Sa Fremgangsmåde til oprensning af fc-holdige proteiner
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
AU2012213240A1 (en) 2011-02-01 2013-08-15 Cancer Research Technology Limited Anti-TACE antibody molecules and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148992T1 (de) * 1989-08-16 1997-03-15 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
JPH05501351A (ja) * 1989-08-16 1993-03-18 カイロン　コーポレイション プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用
WO1992000378A1 (fr) * 1990-06-22 1992-01-09 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Sequence d'adn pour une protease de serine et objets s'y rapportant
WO1992002822A1 (fr) * 1990-08-06 1992-02-20 Cetus Corporation Procedes d'identification d'inhibiteurs de convertase de cytokine
EP0648225A1 (fr) * 1992-06-25 1995-04-19 Chiron Corporation Compositions d'inhibition de la formation d'hormones proteiniques et leurs utilisations
CA2185162A1 (fr) * 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions pour inhiber la formation de tnf et leur emploi
JP2000507943A (ja) * 1996-03-26 2000-06-27 グラクソ、グループ、リミテッド 腫瘍壊死因子αコンバーターゼ

Also Published As

Publication number Publication date
DE69633231T2 (de) 2005-08-04
CA2222650A1 (fr) 1996-12-27
NO975438D0 (no) 1997-11-26
EP0830130B9 (fr) 2004-12-29
EP0830130A1 (fr) 1998-03-25
AU6378196A (en) 1997-01-09
CA2222650C (fr) 2009-10-13
JP2002515020A (ja) 2002-05-21
MX9709744A (es) 1998-07-31
NZ510390A (en) 2002-11-26
NO323623B1 (no) 2007-06-18
IL122305A0 (en) 1998-04-05
EP0830130A4 (fr) 2000-03-29
ATE274346T1 (de) 2004-09-15
DE69633231D1 (de) 2004-09-30
EP0830130B1 (fr) 2004-08-25
NZ312285A (en) 2001-04-27
AU712759B2 (en) 1999-11-18
PT830130E (pt) 2004-11-30
AU712759C (en) 2001-08-09
WO1996041624A1 (fr) 1996-12-27
ES2227598T3 (es) 2005-04-01
NO975438L (no) 1998-02-06
DK0830130T3 (da) 2004-12-20

Similar Documents

Publication Publication Date Title
US7695948B2 (en) Antibodies that bind TNF-α converting enzyme
JP4326022B2 (ja) ＴＮＦ−α転換酵素
US5830742A (en) TNF-α converting enzyme
US7049412B1 (en) Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using same
JP2000506005A (ja) ２ｆ１と呼ばれる受容体タンパク質
JP2003502006A (ja) Ｉｌ−１７ｒｈｄｎａ及びポリペプチド
JP2002500011A (ja) Ｖ２０１ｄｎａ及びポリペプチド
AU752369B2 (en) TNF-alpha converting enzyme
JP2002508969A (ja) 精巣特異的ヒトｓｖｐｈ１−８プロテイナーゼ
WO1999035264A1 (fr) Adn codant h14, et polypeptides h14
JP2002524046A (ja) キナーゼ作用を有するポリペプチドをコードするマウスｄｎａ分子
JP2001526915A (ja) Ｖ１９６ｄｎａ及びポリペプチド
JP2001521742A (ja) Ｓｖｐｈ１−２６ｄｎａおよびポリペプチド
MXPA97009744A (en) Enzima convertidora tnf-a
JP2002500012A (ja) Ｖ１９７ｄｎａ及びポリペプチド

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060627

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071024

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090525

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090609

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120619

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees